Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Capital Expenditures (2016 - 2025)

Fate Therapeutics' Capital Expenditures history spans 14 years, with the latest figure at $5.6 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 678.01% year-over-year to $5.6 million; the TTM value through Dec 2025 reached $6.0 million, up 715.48%, while the annual FY2025 figure was $6.0 million, 715.48% up from the prior year.
  • Capital Expenditures reached $5.6 million in Q4 2025 per FATE's latest filing, up from -$2.2 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $33.6 million in Q4 2022 to a low of -$28.0 million in Q4 2021.
  • Average Capital Expenditures over 5 years is $2.3 million, with a median of $610000.0 recorded in 2023.
  • Peak YoY movement for Capital Expenditures: crashed 2281.94% in 2021, then soared 4578.57% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at -$28.0 million in 2021, then surged by 220.08% to $33.6 million in 2022, then tumbled by 117.79% to -$6.0 million in 2023, then skyrocketed by 111.96% to $714000.0 in 2024, then soared by 678.01% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Capital Expenditures are $5.6 million (Q4 2025), -$2.2 million (Q3 2025), and $1.9 million (Q2 2025).